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ABSTRACT  
In the UK 90% of patients with hereditary haemochromatosis (HH) are homozygous for HFE 
C282Y as are 1 in 150 people in the general population. However only a minority of these will 
develop clinical haemochromatosis. Iron loss modifies iron accumulation but so may other genetic 
factors.  Haptoglobin (Hp) exists in three major types (Hp 1-1,Hp 2-1 or Hp 2-2) and binds free 
plasma haemoglobin. Hp 2-2 in men has been shown to be associated with increased 
macrophage iron accumulation and serum ferritin concentration.  Furthermore, the frequency of 
Hp 2-2 has been shown to be increased in patients with HH.  We determined Hp types by 
polyacrylamide gel electrophoresis and genotyping in 265 blood donor controls and 173 subjects 
homozygous for HFE C282Y.  The latter included 66 blood donors lacking clinical features 
suggestive of haemochromatosis and without a family history and 68 patients presenting clinically 
with haemochromatosis.  To investigate the relationship between iron accumulation and 
haptoglobin type we determined transferrin saturation and serum ferritin concentration in 192 
male, first-time blood donors aged 20-40y who lacked both HFE C282Y and H63D. Hp 
frequencies did not differ between the groups.  Transferrin saturation and serum ferritin 
concentrations did not vary with Hp type.  Hp 2-2 does not appear to be a risk factor for iron 
accumulation in normal men or for the development of disease in subjects homozygous for HFE 
C282Y.   
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INTRODUCTION 
Hereditary haemochromatosis (HH) is an autosomal recessive disorder in which there is iron 
accumulation as a result of increased dietary absorption.  In 1996, the HFE gene was located on 
the short arm of chromosome 6 about 5Mb telomeric to the HLA Class 1 region (Feder et al, 
1996).  It codes for an HLA Class 1 protein and 90% of chromosomes from patients with HH were 
found to have a single mutation of this gene (C282Y).  In the UK over 90% of patients are 
homozygous for this mutation (The UK Haemochromatosis Consortium, 1997) as are about 1 in 
150 people in the general population (Jackson et al, 2001).  
The replacement of cysteine by tyrosine at position 282 in the HFE gene (C282Y) causes the loss 
of a disulphide bridge essential for the protein’s ability to bind to 2-microglobulin (Feder et al, 
1996).  Unlike the wildtype protein, the mutant protein is not expressed at the cell surface.  
Ordinarily, the HFE protein binds to the transferrin receptor to inhibit the binding of iron-loaded 
transferrin, thereby regulating the amount of iron imported into cells.  How this causes the 
enhanced iron absorption in haemochromatosis remains a matter for debate (Roy & Andrews, 
2001;Townsend & Drakesmith, 2002). 
Once diagnosed the excess iron is readily removable by regular venesection and if treatment is 
started before complications have arisen, life expectancy is not reduced (Niederau et al, 1996). 
The frequency of the mutation, the availability of a genetic test and the effective treatment by 
phlebotomy have led to pressure to implement population screening (Burke et al, 1998). However 
the clinical significance of HFE mutations remains uncertain. 
Iron accumulation is influenced by blood loss and diet but studies of twins (Whitfield et al, 2000)  
and in several strains of HFE knock-out mice suggest that genetic factors other than HFE are 
also important (Levy et al, 2000b) (Fleming et al, 2001;Dupic et al, 2002).  A recent study has 
suggested that haptoglobin 2-2 may cause increased iron accumulation in macrophages and 
serum ferritin concentration in men (Langlois et al, 2000).  Furthermore, patients with 
haemochromatosis homozygous for C282Y have been shown to have an increased frequency of 
Hp 2-2 compared with the general population (Van Vlierberghe et al, 2001). 
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Haptoglobin (OMIM No 140100) is an 2 plasma glycoprotein (Polonovski & Jayle, 1938).  It is 
produced mainly by hepatocytes and released into the plasma where it remains for up to 10 days.  
It binds with high affinity in a 1:1 ratio to free oxygenated haemoglobin.  This binding prevents 
loss of free haemoglobin in the urine and protects against oxidative tissue damage.  After removal 
from the circulation by hepatocytes, Kupffer cells and other macrophages, the complex is 
endocytosed (Kristiansen et al, 2001) but haptoglobin is not recycled.  The haptoglobin-
haemoglobin complex is rapidly removed from the plasma with a T½ of 10-30 min (Garby & 
Noyes, 1959).   However, the essential role of haptoglobin appears to relate more to reduction in 
oxidative damage than to the rate of clearance of haemoglobin from the circulation (Lim et al, 
1998). 
 
Haptoglobin is made up of 2  chains and 2  chains linked by disulphide bonds. Smithies first 
proposed that the haptoglobin protein was polymorphic (Smithies, 1955).  There are three major 
types of haptoglobin, Hp 1-1 (86kDa), Hp 2-1 (86-300kDa) and Hp 2-2 (170-1000kDa).  In the 
UK, the allele frequency for Hp1 is approximately 0.4 (Mastana et al, 1994;Hudson et al, 1982). 
Each phenotype is determined by a pair of autosomal, codominant allelic genes found on 
chromosome 16q22, designated Hp1 and Hp2.  The Hp1 allele can be further subdivided into Hp1F, 
which has aspartic acid and lysine at positions 52 and 53 respectively, and Hp1S, which has 
asparagine and glutamic acid (Bowman & Yang, 1987).  Genetic crossover between Hp1 alleles 
has resulted in a partial deletion and duplication, producing a new, elongated Hp2 allele.  This 
duplication has resulted in an additional exon 3 and 4 being translated in the Hp2 product.  The 
Hp1 gene encodes the 1 subunit (approx 8.86kDa), and the Hp2 gene encodes the 2 subunit 
(approx 17.3kDa).   
Many studies implicate haptoglobin phenotype as a possible contributor towards the risk of 
developing disease (Langlois & Delanghe, 1996).  Haptoglobin has also been implicated as a 
factor modifying the phenotype in hereditary haemochromatosis as Hp 2-2 was over-represented 
in haemochromatosis patients homozygous for the C282Y mutation, and these patients had 
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higher serum iron and ferritin concentrations than patients with Hp2-1 and 1-1(Van Vlierberghe et 
al, 2001).  
In the present study, we have determined the haptoglobin types of subjects homozygous for HFE 
C282Y, a control group of blood donors not homozygous for HFE C282Y and male first time 
blood donors aged 20-40 y who lacked HFE C282Y and H63D mutations.  We have compared 
the transferrin saturation and serum ferritin concentrations between haptoglobin types within each 
group. 
 
 
MATERIALS AND METHODS 
Sample Selection 
Whole blood and serum samples were available from 10,500 consenting blood donors from South 
Wales who had participated in a research-based genetic screening programme (Jackson et al, 
2001).  Among these donors, 72 were found to be homozygous for HFE C282Y.  Initially, both 
blood and serum samples were available from these donors.   The control group consisted of 265 
randomly selected samples from blood donors (Jackson et al, 2001), none of whom were 
homozygous for C282Y. Samples were available from unrelated patients homozygous for HFE 
C282Y who presented clinically with haemochromatosis in South Wales (McCune et al, 2002).   A 
total number of 173 subjects homozygous for C282Y included 68 of these index patients, 66 
blood donors and 39 individuals discovered through family screening of both groups.  In addition, 
192 samples were tested from male first time blood donors aged 20-40y who lacked the C282Y 
and H63D mutations of the HFE gene.  When available, serum was used to determine Hp 
phenotypes but for many blood donors only frozen whole blood was available and a method of 
genotyping was developed for this study.  The blood donor study and the study of families of 
C282Y homozygous individuals received approval from the local ethical committee.   
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Measurement Of Transferrin Saturation And Serum Ferritin Concentration 
For blood donor serum iron concentration, unsaturated iron binding capacity, transferrin 
saturation and serum ferritin concentration were determined as described by Worwood 
(Worwood, 2001).  For the patients, only presentation values were included.  The assays were 
carried out in several hospitals in South Wales. 
 
HFE Genotyping  
HFE genotypes of all blood donor samples included in this study were determined by PCR using 
the method of Guttridge et al (Guttridge et al, 1998).  For patients, HFE genotypes were 
determined by heteroduplex analyses (Jackson et al, 1997;Worwood et al, 1999).  
 
Haptoglobin genotyping 
Frozen whole blood (500 L) was added to an equal volume of cell lysis buffer (Tris-HCl 10 
mmolL-1 pH 8.0, sucrose 11% w/v, MgCl2 5 mmolL-1, Triton X-100 1% v/v).  After vortexing briefly 
and incubating at room temperature (RT) for 2 min, the nuclei were harvested by centrifugation 
(Heraeus microfuge 6,000 rpm, 2 min, RT).  The supernatant was discarded, and the nuclei were 
resuspended by briefly vortexing in cell lysis buffer (500 L) and again centrifuged.  The 
supernatant was discarded, and the nuclei gently resuspended in 300 L nuclei lysis buffer (Tris-
HCl pH 8.0 10 mmolL-1, EDTA 10 mmolL-1, sodium citrate 10 mmolL-1, SDS 1% w/v).  NaCl (6 
molL-1, 100 L) and then chloroform (500 L) were added.  The mixture was inverted gently until 
a uniform emulsion formed and this was centrifuged at 6,000 rpm, 5 min, RT.  A portion of the 
upper aqueous layer (300 L) was decanted into absolute ethanol (600 L) and was then mixed 
by gentle inversion until the high molecular weight DNA had precipitated as a small, fibrous ball.  
The DNA was transferred to sterile water (25 L), dissolved at 4oC for 3 h or at RT for 1 h, and 
the concentration was then determined by dilution of an aliquot (10L) in water (1mL) followed by 
UV spectrometry. 
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The Hp2 cDNA (Genbank Entry: NT_010494. Homo sapiens chromosome 16) starts at position 
1152337 (preceding Exon 1) and ends at position 1146076 (the last amino acid of Exon 5).  The 
Hp2 allele runs in the 3’ to 5’ direction on the reverse complement strand of chromosome 16.  
Figure 1 is a diagrammatic representation of the Hp2 allele indicating the positions of exons and 
introns.  Using this diagram, we estimated the approximate sizes of the bands produced by the 
primers annealing at Exons 2 and 5.  Since Hp2 is completely documented, we were confident of 
our prediction of a 4.37Kb band.  However, for Hp1 only the cDNA sequence was available.  We 
estimated the size of the predicted band by eliminating any combination of exon 3 (i and ii) and 4 
(i and ii) and their introns in turn, all of which gave an approximate size of 3.0kb.   
Primers Hp-F (5’ CTGCTCTGGGGACAGCTTTTTGCAGTGG 3’) and Hp-R (5’ 
TGGTCAGTAAATTTAAAATTGGCATTTC 3’) exploit the size difference due to the extra two 
exons of the Hp2 allele.  Primer design took into consideration the haptoglobin-related gene 
(HpR), which is highly homologous with the haptoglobin gene.  Long primers were designed with 
3’ ends that were mismatched against HpR. 
 
Approximately 250ng of high molecular weight DNA was amplified using the Hp-F and Hp-R 
primers in a 15L reaction mix consisting of 1x PCR Buffer II and 2.25mM MgCl2 (GeneAmp®, 
Perkin Elmer), 0.5mM dNTPs (GeneAmp®, Applied Biosystems), 0.6 M of each primer (Oswel 
DNA Service, Southampton) and 1 unit of Amplitaq DNA Polymerase (Applied Biosystems). 
After a "hot start" at 92ºC for 2 min, there were 28 cycles of denaturing at 92ºC for 30 s, 
annealing at 62ºC for 30 s and extension at 68ºC for 10 min.  There was a 20 s increment in the 
extension step of each cycle.  The PCR was performed on a Phoenix thermocycler (Helena 
Biosciences).  PCR product (4L) was added to 1.5L loading buffer containing bromophenol 
blue and loaded on a 0.8% (w/v) agarose gel (8cmx10cmx1cm) in 0.5X TBE (Tris-borate-EDTA) 
buffer pH 8.0 containing ethidium bromide for electrophoresis at 60V for 3 h.  The size marker 
was a 1Kb DNA ladder marker (Gibco BRL). 
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Haptoglobin Phenotyping 
A red cell lysate containing free haemoglobin was prepared by adding 500L of whole blood to 
500L of water and centrifuging (Heraeus microfuge 13,000rpm, 5 min).  The supernatant was 
removed, added to 500L of water and re-centrifuged.  The supernatant was removed and 1.5L 
was added to 15L of serum and left for 10 min for the haptoglobin-haemoglobin complexes to 
form.  The 15L sample was added to 1.5L loading dye and loaded on to a 2mm (16cmx16cm) 
5% polyacrylamide gel (37.5:1 polyacrylamide gel, Appligene) for electrophoresis in 1xTBE buffer 
pH 8.0 at 200V for 3 h.   The gel was removed and incubated for 1 h with a solution of 15mL 
1xTBE in which was dissolved 1 tablet of 3,3’-diaminobenzidine (Sigma) and 15L hydrogen 
peroxide (Sigma), in order to detect haem. 
 
Analysis Of Results 
The distributions of haptoglobin frequencies in groups of subjects were compared using the Chi2 
test.  Transferrin saturations are given as mean  SD and mean values are compared using the 
two sample t-Test assuming unequal variance.  Serum ferritin concentrations were not normally 
distributed so the median and the ranges are given.  Median values were compared using the 
Mann-Whitney U Test.  A probability of <0.05 was taken to indicate a significant difference. 
 
 
RESULTS 
Genotyping 
We developed a new method of haptoglobin genotyping using frozen whole blood and a single 
PCR that exploits the 1.7Kb size difference between the product of the Hp1 and Hp2 alleles.  The 
PCR method was validated by testing 86 samples that had been previously typed using PAGE. 
There was 100% agreement.  Fig. 2a shows the PCR products for 6 subjects.  The product 
present in samples 1 & 2 is approximately 4.7kb in size while the product present in samples 5 & 
6 is approximately 3.0kb in size.   The larger product was less intense, since it was less 
favourably amplified during the long distance PCR.   
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The Hp0 type has a gene deletion from the Hp promoter to the 5’ end of HpR (Koda et al, 1998) 
and would be misinterpreted as a failure of the PCR in the very rare case of a homozygous 
deletion.  Sometimes cases of hypo-haptoglobinaemia may be compound heterozygotes 
(Hp2/Hp0) (Koda et al, 1998).  These would be considered to be Hp 2-2 type after PCR.  
However, the frequency of Hp0 is very low in European Caucasians (Langlois & Delanghe, 1996).  
Furthermore, the observed haptoglobin frequencies did not differ from the expected Hardy-
Weinberg distribution calculated by assuming that there were two genotypes, Hp1 and Hp2.  The 
haptoglobin frequencies in controls are those expected for a Northern European population 
(Langlois & Delanghe, 1996). 
 
Phenotyping  
Fig. 2b shows the PAGE results for the serum of the same subjects tested in Fig 2a.   
Haptoglobin phenotypes were easily distinguishable by the number and position of the bands 
stained.  The Hp 1-1 phenotype has a single band that rapidly migrates towards the cathode.  
The Hp 2-2 phenotype has a series of slower bands, while the Hp 2-1 phenotype has a mixture of 
both types.  The Hp 1-1 band has a similar mobility to that of free haemoglobin (which must 
always be present to ensure staining of all haptoglobin bands).  Subjects carrying Hp0 may have 
anhaptoglobinaemia or may have very low plasma concentrations so only the free haemoglobin 
will electrophorese on the gel and be stained.  Subjects with Hp0 may therefore be reported as 
Hp 1-1 but the frequency of Hp0 is very low in European populations (see above).   
 
Haptoglobin Types In Blood Donors And Subjects Homozygous For C282Y 
Table 1 shows the haptoglobin types for the control subjects (blood donors), first time male blood 
donors, all subjects homozygous for C282Y, blood donors homozygous for C282Y and unrelated 
patients homozygous for C282Y.  There were no significant differences for haptoglobin 
distribution between any pair of groups. Haptoglobin frequencies for males and females within 
each group were not significantly different.  When male and female subjects were compared 
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between groups there were no significant differences.  The greatest % differences between 
groups were for Hp 1-1.  When frequencies were compared using a 2x2 table (Hp 1-1 and others) 
there were no significant differences in frequency for all subjects or for males and females 
separately.  There were no significant differences in haptoglobin frequency for subjects who were 
“wildtype” HFE, heterozygotes for H63D or heterozygotes for C282Y in the control blood donor 
group (data not shown). 
 
Transferrin Saturation, Serum Ferritin Concentrations and Haptoglobin Type 
Table 2 shows the mean transferrin saturation and the median serum ferritin concentration for 
each group according to haptoglobin type and sex.  Information about iron status was available 
for almost all controls and for the blood donors homozygous for C282Y but values were not 
available for all patients at presentation. There were no differences in iron status for each 
haptoglobin type within the groups of subjects, even when divided into males and females. 
We also examined the variation of transferrin saturation and serum ferritin concentration in male, 
first time blood donors aged 20-40y who lacked both the C282Y and H63D mutations of the HFE 
gene (Table 3).  There were no significant differences in either transferrin saturation or serum 
ferritin concentration between the haptoglobin types. 
 
DISCUSSION 
It was necessary to develop a method to determine haptoglobin types by genotyping, because 
many of the subjects had only frozen whole blood available. Recently a method of genotyping 
based on similar principles has been described (Koch et al, 2002).  The authors confirmed their 
results using alternative PCR protocols.  Both genotyping and the PAGE methods are suitable for 
healthy subjects of European origin where the frequency of Hp0 is very low.  
 
Jackson et al (Jackson et al, 2001) tested 10,500 blood donors from South Wales and identified 
72 who were homozygous for HFE C282Y.  None were aware of any family history of iron 
overload and none had clinical features suggestive of haemochromatosis.  Most of the men, but 
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only 45% of the women, had a transferrin saturation > 50%.  Only 5 had both transferrin 
saturations and serum ferritin concentrations raised above the clinical threshold for iron overload 
(> 200 g/L for pre-menopausal women, > 300 g/L for men and post-menopausal women).  
These findings suggest a low penetrance for homozygosity for C282Y for both iron overload and 
disease.  However, the mean age of these blood donors was 37y (range 17-66), below the mean 
age of 50y for diagnosis of haemochromatosis (Mcdonnell et al, 1999).  In order to assess the 
life-long impact of haemochromatosis on morbidity a survey of hereditary haemochromatosis as a 
clinical condition was carried out in South Wales.  It was calculated that only 1.2% of adult C282Y 
homozygotes have received a confirmed diagnosis (McCune et al, 2002), suggesting that the 
morbidity associated with homozygosity of C282Y in our region was low.  Restricting the 
calculation to men over 45y, the figure rose to 2.8%.  Similar conclusions about morbidity in 
haemochromatosis were reached by Beutler et al in a study of 152 C282Y homozygotes from 
41,038 subjects presenting to a Health Appraisal Clinic in California (Beutler et al, 2002a).  
In healthy men Hp 2-2 was found to be associated with a higher transferrin saturation, lower 
transferrin receptor concentrations and increased serum ferritin and macrophage ferritin 
concentrations when compared to men with Hp 1-1 or Hp 1-2 (Langlois et al, 2000).  The present 
study does not support this finding.  However, neither blood donors nor patients with 
haemochromatosis provide a suitable group to examine a possible relationship between iron 
status and Hp type, since blood donation reduces iron stores and HH patients will have varying 
degrees of iron overload depending upon the age at diagnosis, among other factors.  We have 
therefore examined the variation of transferrin saturation and serum ferritin concentration in male, 
first time blood donors aged 20-40 y who lacked both the C282Y and H63D mutations of the HFE 
gene so that the HFE genotype did not influence measures of iron status (Jackson et al, 2001).  
An estimated 3.9% will carry HFE S65C but this mutation is not associated with changes in 
transferrin saturation or serum ferritin compared to HFE “wildtype” blood donors (Carter et al 
unpublished).  There would be little influence of blood loss, either pathological or as a result of 
blood donation in these healthy young men.  There were no significant differences in either 
transferrin saturation or serum ferritin concentration between the Hp types. 
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There have been numerous reports of associations between Hp phenotypes and diseases 
(Langlois & Delanghe, 1996).  There are no reports suggesting that the possession of a particular 
Hp type is a risk factor for arthritis or diabetes.  However, the Hp 1-1 phenotype has been 
associated with protection against vascular complications in both Type I (Levy et al, 2000a) and 
Type II (Nakhoul et al, 2001) diabetes.  Zhao and Zhang found that Hp1-1 was over-represented 
in 107 patients with cirrhosis of the liver compared with 552 normal adults (Relative risk 3.3, p = 
2x10-4)(Zhao & Zhang, 1993).  Zipprich et al found an increased frequency of Hp1-1 in 100 
German patients with chronic, non-alcoholic liver disease but not in 90 patients with cirrhosis 
when compared with 1726 controls (Zipprich et al, 1986).  There appear to be no clear 
associations between Hp type and risk of the major clinical manifestations of HH. 
Differences in turnover and haemoglobin binding may explain both changes in iron storage and in 
disease risk for Hp 2-2.  The Hp 1-1 phenotype binds free haemoglobin more efficiently than 
either Hp 2-1 or Hp 2-2 (Langlois & Delanghe, 1996).  It also has unrestricted access to tissues, 
possibly due to its smaller size and consequent ability to migrate across the endothelial cell 
barrier.  These advantages may contribute to a more effective clearance of free haemoglobin 
from the plasma than is achieved by the other two phenotypes.  However, it has been reported 
(Kristiansen et al, 2001) that Hp 2-2 complexed with haemoglobin exhibits a higher affinity for the 
CD163 receptor than the other complexed haptoglobin phenotypes, which would suggest a 
preferential delivery of haemoglobin complex to the macrophage.  Subjects with the Hp 2-2 
phenotype may therefore have a tendency to accumulate more iron in macrophages (Langlois et 
al, 2000).  Plasma vitamin C concentrations were lowest in the Hp 2-2 phenotype (Langlois et al, 
1997).  These authors suggested that this may be a consequence of the weaker binding of 
haemoglobin by Hp 2-2 and the weaker anti-oxidative capacity. 
 
The above findings provide a basis for differences in the handling of haemoglobin iron by the 
major haptoglobin types.  However, our studies of normal men who had not donated blood and 
 13 
lacked the HFE mutation, and subjects homozygous for HFE C282Y do not suggest that 
haptoglobin is a “disease-modifying” gene in haemochromatosis.   
 
These findings confirm two recent reports. A recent study reported no differences in the 
frequency of Hp 2-2 between subjects homozygous for HFE C282Y and controls lacking the HFE 
mutations (Beutler et al, 2002b). Among subjects of African origin iron status did not vary with Hp 
type (Kasvosve et al, 2002).  Beutler et al (2002) suggest that conflicting conclusions about the 
frequency of Hp 2-2 in haemochromatosis may reflect differences in ascertainment.  However in 
our study we did not find significant differences in frequency between cases “discovered” by 
genetic testing to be homozygous for HFE C282Y and the patients presenting clinically with signs 
and symptoms of iron overload who were homozygous for HFE C282Y. 
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Figure 1 
Model of the structure of Hp2 cDNA based upon Genbank entry NT_010494.   
Exons are numbered 1 to 5 with their approximate sizes below.  Introns are labelled A to F along 
with approximate intron sizes.    
PCR primers extend in the direction indicated by arrows. 
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    M  B      1    2 3     4     5 6         
 
 
 
 
Figure 2a: Haptoglobin genotyping using long distance PCR 
Samples 1 & 2 are homozygous for the Hp2 allele, samples 3 & 4 are heterozygous for the Hp1 
and Hp2 alleles and samples 5 & 6 are homozygous for the Hp1 allele.  
M = 1kb DNA ladder ; B = water blank.   
 
← Top product = 4.37Kb 
←Bottom product = 3.0Kb 
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Figure 2b: Haptoglobin typing using polyacrylamide gel electrophoresis 
The samples are the same as those depicted in Figure 2a. 
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GROUP No. OF 
SUBJECTS 
FEMALE / MALE HP 1-1 HP 2-1 HP 2-2 
Blood donor controls 265 140 / 125 43 
(16.2%) 
124 
(46.8%) 
98 
(37%) 
Male first time blood 
donors 
192 N/A 27 
(14.1%) 
87 
(45.3%) 
78 
(40.6%) 
All homozygous for C282Y 173 76 / 97 26  
(15%) 
76 
(43.9%) 
71 
(41%) 
Blood donors homozygous 
for C282Y 
66 39 / 27 14 
(21.2%) 
32 
(48.5%) 
20 
(30.3%) 
Patients homozygous for 
C282Y 
68 22 / 46 8 
(11.8%) 
34 
(50%) 
26 
(38.2%) 
 
Table 1 
Haptoglobin types in blood donors and patients with haemochromatosis. 
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GROUP SEX Hp 
Type 
n TS (%) 
mean  SD 
n s Fn (g/L) 
median 
Range 
Blood Donors Male 1-1 24 31 11 24 104 34 – 183 
2-1 59 31  15 61 96 6 – 299 
2-2 40 31  11 40 87 24 – 207 
Female 1-1 19 25  12 19 57 9 – 116 
2-1 63 24  11 63 37 7 – 301 
2-2 57 25 11 58 41 9 – 137 
Blood Donors – 
C282Y 
homozygous 
Male 1-1 5 56  15 5 141 51 – 374 
2-1 14 63  16 14 221 14 – 650 
2-2 8 69  23 8 135 85 – 410 
Female 1-1 9 56  25 9 58 11 – 238 
2-1 18 49  20 18 68 13 – 418 
2-2 12 50  19 10 96 8 – 195 
Patients – 
C282Y 
homozygous 
Male 1-1 4 69  13 4 1215 620 – 3675 
2-1 12 78  13 15 1585 494 – 3422 
2-2 10 83  9 11 1790 540 – 5738 
Female 1-1 1 89 2 980 655 – 1305 
2-1 4 81  15 4 991 376 – 3002 
2-2 7 74  15 8 845 263 – 2720 
 
Table 2 
Transferrin saturation and serum ferritin concentration according to Hp type. 
The numbers tested are samples for which either transferrin saturation or serum ferritin 
concentrations were available. 
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Hp type Number Transferrin Saturation (%) 
mean  SD 
Serum ferritin (g/L)  
median and range 
 1-1 27 28  10 112 (25 – 193) 
2-1 87 30  11 100 (34 – 263) 
2-2 78 29  9 108 (26 – 223) 
 
Table 3 
Transferrin saturation and serum ferritin concentration in male first time blood donors lacking HFE 
C282Y and H63D and aged 20-40 y. 
 
 20 
 
REFERENCES 
 
Beutler,E., Felitti,V.J., Koziol,J.A., Ho,N.J., & Gelbart,T. (2002a) Penetrance of 845G>A (C282Y) 
HFE hereditary haemochromatosis mutation in the USA. Lancet, 359, 211-218. 
Beutler,E., Gelbart,T., & Lee,P. (2002b) Haptoglobin polymorphism and iron homeostasis. Clinical 
Chemistry, 48, 2232-2235. 
Bowman,B.H. & Yang,F. (1987) DNA sequencing and chromosomal locations of human plasma 
protein genes. The plasma proteins V: Structure, function and genetic control (ed. by F. 
W. Putman), pp. 1-48. Academic Press. 
Burke,W., Thompson,E., Khoury,M.J., Mcdonnell,S.M., Press,N., Adams,P.C., Barton,J.C., 
Beutler,E., Brittenham,G., Buchanan,A., Clayton,E.W., Cogswell,M.E., Meslin,E.M., 
Motulsky,A.G., Powell,L.W., Sigal,E., Wilfond,B.S., & Collins,F.S. (1998) Hereditary 
hemochromatosis: gene discovery and its implications for population-based screening. 
Jama-Journal of the American Medical Association, 280, 172-178. 
Dupic,F., Fruchon,S., Bensaid,M., Borot,N., Radosavljevic,M., Loreal,O., Brissot,P., Gilfillan,S., 
Bahram,S., Coppin,H., & Roth,M.P. (2002) Inactivation of the hemochromatosis gene 
differentially regulates duodenal expression of iron-related mRNAs between mouse 
strains. Gastroenterology , 122, 745-751. 
Feder,J.N., Gnirke,A., Thomas,W., Tsuchihashi,Z., Ruddy,D.A., Basava,A., Dormishian,F., 
Domingo,R., Ellis,M.C., Fullan,A., Hinton,L.M., Jones,N.L., Kimmel,B.E., Kronmal,G.S., 
Lauer,P., Lee,V.K., Loeb,D.B., Mapa,F.A., McClelland,E., Meyer,N.C., Mintier,G.A., 
Moeller,N., Moore,T., Morikang,E., Prass,C.E., Quintana,L., Starnes,S.M., 
Schatzman,R.C., Brunke,K.J., Drayna,D.T., Risch,N.J., Bacon,B.R., & Wolff,R.K. (1996) 
A novel MHC class-1 like gene is mutated in patients with hereditary haemochromatosis. 
Nature Genetics, 13, 399-408. 
Fleming,R.E., Holden,C.C., Tomatsu,S., Waheed,A., Brunt,E.M., Britton,R.S., Bacon,B.R., 
Roopenian,D.C., & Sly,W.S. (2001) Mouse strain differences determine severity of iron 
accumulation in Hfe knockout model of hereditary hemochromatosis. Proceedings of the 
National Academy of Sciences of the United States of America, 98, 2707-2711. 
Garby,L. & Noyes,W.D. (1959) Studies on hemoglobin metabolism.1. The kinetic properties of the 
plasma hemoglobin pool in normal man. Journal of Clinical Investigation, 38, 1479-1483. 
Guttridge,M.G., Thompson,J., Worwood,M., & Darke,C. (1998) Rapid detection of genetic 
mutations associated with haemochromatosis. Vox Sanguinis, 75, 253-256. 
Hudson,B.L., Sunderland,E., Cartwright,R.A., Benson,E.A., Smiddy,F.G., & Cartwright,S.C. 
(1982) Haptoglobin phenotypes in two series of breast cancer patients. Human Heredity, 
32, 219-221. 
Jackson,H.A., Bowen,D.J., & Worwood,M. (1997) Rapid genetic screening for haemochromatosis 
using heteroduplex technology. British Journal of Haematology, 98, 856-859. 
Jackson,H.A., Carter,K., Darke,C., Guttridge,M.G., Ravine,D., Hutton,R.D., Napier,J.A., & 
Worwood,M. (2001) HFE mutations, iron deficiency and overload in 10,500 blood donors. 
British Journal of Haematology, 114, 474-484. 
 21 
Kasvosve,I., Gordeuk,V.R., Delanghe,J.R., Gomo,Z.A., Gangaidzo,I.T., Khumalo,H., Moyo,V.M., 
Saungweme,T., Mvundura,E., & Boelaert,J.R. (2002) Iron status in black persons is not 
influenced by haptoglobin polymorphism.  Clinical Chemistry and Laboratory Medicine, 
40, 810-813. 
Koch,W., Latz,W., Eichinger,M., Roguin,A., Levy,A.P., Schömig,A., & Kastrati,A. (2002) 
Genotyping of the common haptoglobin Hp1/2 polymorphism based on PCR. Clinical 
Chemistry, 48, 1377-1382. 
Koda,Y., Soejima,M., Yoshioka,N., & Kimura,H. (1998) The haptoglobin-gene deletion 
responsible for anhaptoglobinemia. American Journal of Human Genetics, 62, 245-252. 
Kristiansen,M., Graversen,J.H., Jacobsen,C., Sonne,O., Hoffman,H.J., Law,S.K.A., & 
Moestrup,S.K. (2001) Identification of the haemoglobin scavenger receptor. Nature, 409, 
198-201. 
Langlois,M.R. & Delanghe,J.R. (1996) Biological and clinical significance of haptoglobin 
polymorphism in humans. Clinical Chemistry, 42, 1589-1600. 
Langlois,M.R., Delanghe,J.R., DeBuyzere,M.L., Bernard,D.R., & Ouyang,J. (1997) Effect of 
haptoglobin on the metabolism of vitamin C. American Journal of Clinical Nutrition, 66, 
606-610. 
Langlois,M.R., Martin,M.E., Boelaert,J.R., Beaumont,C., Taes,Y.E., De Buyzere,D.R., 
Neels,H.M., & Delanghe,J.R. (2000) The haptoglobin 2-2 phenotype affects serum 
markers of iron status in healthy males. Clinical Chemistry, 46, 1619-1625. 
Levy,A.P., Roguin,A., Hochberg,I., Herer,P., Marsh,S., Nakhoul,F.M., & Skorecki,K. (2000a) 
Haptoglobin phenotype and vascular complications in patients with diabetes. New 
England Journal of Medicine, 343, 969-970. 
Levy,J.E., Montross,L.K., & Andrews,N.C. (2000b) Genes that modify the hemochromatosis 
phenotype in mice. Journal of Clinical Investigation, 105, 1209-1216. 
Lim,S.K., Kim,H., Lim,S.K., Ali,A.B., Lim,Y.K., Wang,Y., Chong,S.M., Constantini,F., & 
Baumman,H. (1998) Increased susceptibility in Hp knockout mice during acute 
hemolysis. Blood, 92, 1870-1877. 
Mastana,S.S., Bernal,J.E., Onyemelukwe,G.C., & Papiha,S.S. (1994) Haptoglobin subtypes 
among four different populations. Human Heredity, 44, 10-13. 
McCune,C.A., Al-Jader,L.N., May,A., Hayes,S.L., Jackson,H.A., & Worwood,M. (2002) Hereditary 
haemochromatosis: only 1% of adult HFE C282Y homozygotes in South Wales have a 
clinical diagnosis of iron overload. Human Genetics, 111, 538-543. 
Mcdonnell,S.M., Preston,B.L., Jewell,S.A., Barton,J.C., Edwards,C.Q., Adams,P.C., & Yip,R. 
(1999) A survey of 2,851 patients with hemochromatosis: symptoms and response to 
treatment. American journal of Medicine, 106, 619-624. 
Nakhoul,F.M., Zoabi,R., Kanter,Y., Zoabi,M., Skorecki,K., Hochberg,I., Leibu,R., Miller,B.P., & 
Levy,A.P. (2001) Haptoglobin phenotype and diabetic nephropathy. Diabetologia, 44, 
602-604. 
 22 
Niederau,C., Fischer,R., Purschel,A., Stremmel,W., Haussinger,D., & Strohmeyer,G. (1996) 
Long-term survival in patients with hereditary hemochromatosis. Gastroenterology, 110, 
1107-1119. 
Polonovski,M. & Jayle,M.F. (1938) Existence dans le plasma sanguin d'une substance activant 
l'action peroxydasique de l'hémoglobine. Comptes Rendues des Séances de la Société 
de Biologie, 129, 457-460. 
Roy,C.N. & Andrews,N.C. (2001) Recent advances in disorders of iron metabolism: mutations, 
mechanisms and modifiers. Human Molecular Genetics, 10, 2181-2186. 
Smithies,O. (1955) Zone electrophoresis in starch gels: group variations in the serum proteins of 
normal human adults. Biochemical Journal, 61, 629-641. 
The UK Haemochromatosis Consortium (1997) A simple genetic test identifies 90% of UK 
patients with haemochromatosis. Gut, 41, 841-844. 
Townsend,A. & Drakesmith,H. (2002) Role of HFE in iron metabolism, hereditary 
haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet, 
359, 786-790. 
Van Vlierberghe,H., Langlois,M.R., Delanghe,J.R., Horsmans,Y., Michielsen,P., Henrion,J., 
Cartuyvels,R., Billiet,J., De Vos,M., & Leroux-Roels,G. (2001) Haptoglobin phenotype 2-2 
overrepresentation in Cys282Tyr hemochromatotic patients. Journal of Hepatology, 35, 
707-711. 
Whitfield,J.B., Cullen,L.M., Jazwinska,E.C., Powell,L.W., Heath,A.C., Zhu,G., Duffy,D.L., & 
Martin,N.G. (2000) Effects of HFE C282Y and H63D polymorphisms and polygenic 
background on iron stores in a large community sample of twins. American Journal of 
Human Genetics, 66, 1246-1258. 
Worwood,M. (2001) Iron deficiency anaemia and iron overload. Dacie and Lewis Practical 
Haematology (ed. by S. M. Lewis, B. J. Bain, & I. Bates), pp. 115-128. Churchill 
Livingstone. 
Worwood,M., Jackson,H.A., Feeney,G.P., Edwards,C., & Bowen,D.J. (1999) A single tube 
heteroduplex PCR for the common HFE genotypes. Blood, 94, 405a. 
Zhao,H. & Zhang,G. (1993) Haptoglobin groups and cirrhosis of the liver. Human Heredity, 43, 
134-136. 
Zipprich,B., Giebelmann,R., Tolani,K., Schmidt,W., Konigstedt,B., Scheibe,E., & Nilius,R. (1986) 
Haptoglobin type and liver disease. Hepatogastroenterology, 33, 196-198. 
 
